CD36 and breast cancer: Tumor-recruited M-LECPs retained this profile in vivo as shown by expression of prominent fusogenic markers SIRP-a, CD36, and DAP12 in 60–90% of LYVE-1+ cells in mouse and human BC (Figure 3 and Figure 4).